01985nas a2200217   4500008003900000245005300039210005300092260001100145300001200156490000700168520128300175653001101458653005101469653002501520653004301545653004501588653004501633653003201678100001201710856004501722       1996                          d00aMalignant melanoma in organ allograft recipients0 aMalignant melanoma in organ allograft recipients  cJan 27  a274 - 80 v613 aThree groups of tumors were studied. The first group was melanomas inadvertently transmitted from donors. Brain metastases from melanoma were often misdiagnosed in the donors as primary brain tumors or cerebral hemorrhage. Eleven donors provided organs to 20 recipients of whom 3 never manifested evidence of melanoma, 1 showed local spread of tumor beyond the allograft, and 16 had metastases. Of the last group 11 died from melanoma, but 4 patients had complete remissions following transplant nephrectomy and discontinuation of immunosuppressive therapy. The second group was Melanomas treated pretransplantation. Thirty patients had cutaneous melanomas and one an ocular melanoma. Six patients (19%) had recurrences posttransplantation. Three were treated  0.76 mm by Breslow's technique). Lymph node metastases occurred in 32 patients (20%) with cutaneous melanomas. Fifty patients (30%) with cutaneous melanomas died of their malignancies, as did 5 with melanomas of unknown origin, and 1 with ocular melanoma. The risks of melanoma may be reduced by stringent selection of donors; by waiting at least 5 years between treatment of melanoma and undertaking transplantation; and, perhaps, by reducing sunlight exposure and by early excision of suspicious dysplastic lesions.10aHumans10aKidney Neoplasms / *etiology / physiopathology10aLymphatic Metastasis10aMelanoma / *etiology / physiopathology10aOrgan Transplantation / *adverse effects10aResearch Support, U.S. Gov't, Non-P.H.S.10aTransplantation, Homologous1 aPenn, I  uhttps://notifylibrary.org/reference/1171